Highlighting the AUTOTAC Technology as a Bimodal TPD Platform: Development of ATB2005A as a First-in-Class Tau Aggregate Degrader in Clinical Trials
- Introduction of AutotacBio and the AUTOTAC/ATL platform
- Mechanisms behind ATL-induced, selective autophagy-specific autophagosome biogenesis
- Safety/PK data from Phase 1 clinical trial of ATB2005A